Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year...
Abbott
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm...
Abbott to Acquire Insulin Management Firm Bigfoot Biomedical
Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...
Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip
US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...
Abbott Partners with Sinopharm for Expanded Medical Solutions in China
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical...
Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates
US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1%...
CIIE: Bo’ao Lecheng Zone Announces Partnerships with Multinationals
The 5th China International Import Expo (CIIE) saw the Bo’ao Lecheng Medical Tourism Pilot Zone...
Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance
With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...